Drug Shortage Report for APO-LAMIVUDINE HBV
Report ID | 100278 |
Drug Identification Number | 02393239 |
Brand name | APO-LAMIVUDINE HBV |
Common or Proper name | LAMIVUDINE |
Company Name | APOTEX INC |
Market Status | MARKETED |
Active Ingredient(s) | LAMIVUDINE |
Strength(s) | 100MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 100 BTL |
ATC code | J05AF |
ATC description | DIRECT ACTING ANTIVIRALS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2019-12-02 |
Estimated end date | 2020-03-06 |
Actual end date | 2020-02-21 |
Shortage status | Resolved |
Updated date | 2020-02-25 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 150 SIGNET DRIVE TORONTO, ONTARIO CANADA M9L 1T9 |
Company contact information | Apotex Customer Service - 1-877-427-6839 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2020-02-25 | French | Compare |
v5 | 2020-02-25 | English | Compare |
v4 | 2020-01-31 | French | Compare |
v3 | 2020-01-31 | English | Compare |
v2 | 2019-12-05 | French | Compare |
v1 | 2019-12-05 | English | Compare |
Showing 1 to 6 of 6